Neurology

At the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego, new late-breaking data from a Phase III clinical trial highlighted the efficacy and safety of telitacicept in patients with generalized myasthenia gravis (gMG).

Intravenous fosphenytoin (fPHT) demonstrated rapid and significant pain relief for patients experiencing acute exacerbations of trigeminal neuralgia (TN), according to late-breaking results from the IFT Study presented at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego.

In a new quasi-experimental study aimed at improving pediatric epilepsy care, researchers have found that tele-nursing significantly reduces maternal anxiety and increases self-efficacy after hospital discharge.

At the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego, new data from the TRAILBLAZER-ALZ clinical trial program highlighted critical risk factors and management strategies for amyloid-related imaging abnormalities (ARIA) in patients with early symptomatic Alzheimer’s disease treated with donanemab.

A genome-wide association study (GWAS) presented at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego has identified 778 previously unknown genetic variants associated with migraine, shedding new light on the condition’s genetic underpinnings across racial and ethnic groups.

At the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego, researchers presented late-breaking data from the Inspire Study, a trial exploring spinal cord stimulation (SCS) as a holistic treatment for painful diabetic peripheral neuropathy (pDPN).

New results from the Phase III TEMPO-2 trial, presented at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego, indicate that flexible-dose tavapadon significantly improved motor symptoms and daily functioning in adults with early Parkinson’s disease (PD), compared with placebo.

In hospitalized patients with alcohol withdrawal syndrome (AWS), early addition of phenobarbital to lorazepam-based treatment significantly reduces the length of stay and the need for mechanical ventilation compared to dexmedetomidine, according to a new retrospective study conducted in a U.S. tertiary hospital.